Company: ARMP
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001104659-25-040273
Chunk: 44

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 44
---
 |       ​ | ​ | ​ | ​ |             99,260 | ​ |       ​ | ​ | ​ | ​ | —                                       | ​ | ​ | ​ | ​ | ​ |                       1,813 | ​ |       ​ | ​ | ​ | ​ |   197,740 | ​ |         ​ |   |   |

(1) In accordance with SEC rules, this column represents the aggregate grant date fair value of the restricted stock units granted during 2024 and 2023 computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in Note 10 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the settlement of the restricted stock units or the sale of the common stock underlying such restricted stock units. (2) In accordance with SEC rules, this column represents the aggregate grant date fair value of the option awards granted during 2024 and 2023 computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718 for stock-based compensation transactions. Assumptions used in the calculation of these amounts are included in Note 10 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. These amounts do not reflect the actual economic value that will be realized by the named

29

executive officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. (3) Dr. Kyme was promoted to the role of Chief Business Officer on June 1, 2024. (4) Mr. House was appointed Senior Vice President, Finance and Principal Financial Officer as of August 16, 2024. (5) Dr. Pastagia departed from her role as Chief Medical Officer on November 13, 2024. (6) Mr. Rychlik departed from his role as Vice President, Corporate Controller on September 30, 2024. (7) Amounts reflected in this column for 2024 include 401(k) plan company matching contributions of $8,998 for Dr. Birx, $7,126 for Dr. Kyme, $3,500 for Mr. House, $7